Q4 2024 Evolus Inc Earnings Call Transcript
Key Points
- Evolus Inc (EOLS) achieved profitability in Q4 2024 and for the full year, one year ahead of their goal.
- The company reported revenue growth above 30% for the fifth consecutive year, solidifying its position as the fastest-growing brand in its category.
- Evolus Inc (EOLS) expanded its total addressable market in the US by 78% with FDA approval for Evolus Form and Evolus Smooth.
- The company added over 22,900 new accounts in 2024, bringing the total to more than 15,000 purchasing accounts.
- Evolus Inc (EOLS) has a strong international presence, with significant market share gains in the UK, Australia, and Spain.
- The company anticipates minimal revenue from Evolite in Q2 2025, with the majority expected in the latter half of the year.
- Operating expenses are expected to increase in 2025 to support the launch of new products.
- There is a potential risk of market saturation as Evolus Inc (EOLS) is already in half of the toxin market.
- The company faces challenging market conditions for US facial injectables, as noted by competitors.
- Evolus Inc (EOLS) expects a use of cash in Q1 2025 due to seasonality and inventory stocking for new product launches.
Good afternoon, everyone, and thank you for standing by. Welcome to Evolus fourth quarter in full year 2024 earnings conference call. (Operator Instructions)
I would now like to turn the conference over to Nareg Sagherian, Vice President and head of global investor relations and corporate communications. Please go ahead.
Thank you, operator, and welcome to everyone joining us on today's call to review Elis's fourth quarter and full year 2024 financial results. Our fourth quarter and full year 2024 press release is now on our website at Evolus.com. With me today are David Motati, President and Chief Executive Officer, Louis Avalar, Chief Medical Officer and head of R&D, and Sandra Beaver, Chief Financial Officer.
Today's call will include forward-looking statements. Actual results may differ materially due to risks and uncertainties outlined in our earnings press release and SEC filings. These forward-looking statements are based on
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
